RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000071.xml
PDF herunterladen
Semin Neurol 2001; 21(3): 309-326
DOI: 10.1055/s-2001-17948
DOI: 10.1055/s-2001-17948
Treatment of Mitochondrial Cytopathies
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
18. Oktober 2001 (online)
ABSTRACT
Mitochondrial cytopathies are clinically and biochemically heterogeneous disorders affecting energy production. Because of the diverse symptoms spanning organ systems, the large number of biochemical and genetic defects, and an unpredictable clinical course, there are limited data regarding proven effective therapies. In general, treatments for mitochondrial cytopathies are intended to augment energy production as well as reduce the production of free radicals and other toxic metabolites that further limit the generation of cellular energy. Theoretically, treatment can be aimed at increasing respiratory chain activity by supplementing relative deficiencies of cofactors required for proper functioning. Possible strategies to consider may include dietary management, supplemental vitamins and cofactors, and/or specific medications aimed at a particular symptom.
KEYWORD
Mitochondrial encephalomyopathy - coenzyme Q10 - carnitine - experimental treatment
REFERENCES
- 1 Chinnery P F, Howell N, Lightowlers R N, Turnbull D M. Molecular pathology of MELAS and MERRF: the relationship between mutation load and clinical phenotypes. Brain . 1997; 120 1713-1721
- 2 Lauwers M H, Van Lersberghe C, Camu F. Inhalation anaesthesia and the Kearns-Sayre syndrome. Anaesthesia . 1994; 49 876-878
- 3 Burns A M, Shelly M P. Anaesthesia for patients with mitochondrial myopathy. Anaesthesia . 1989; 44 975-977
- 4 D'Ambra M N, Dedrick D, Savarese J J. Kearns-Sayre syndrome and pancuronium-succinylcholine-induced neuromuscular blockade. Anesthesiology . 1979; 51 343-345
- 5 Casta A, Quackenbush E J, Houck C S. Perioperative white matter degeneration and death in a patient with a defect in mitochondrial oxidative phosphorylation. Anesthesiology . 1997; 87 420-425
- 6 Kitoh T, Mizuno K, Otagiri T, Ichinose A, Sasao J, Goto H. Anesthetic management for a patient with Kearns-Sayre syndrome. Anesth Analg . 1995; 80 1240-1242
- 7 Barohn R J, Clanton T, Sahenk Z, Mendell J R. Recurrent respiratory insufficiency and depressed ventilatory drive complicating mitochondrial myopathies. Neurology . 1990; 40 103-106
- 8 Maslow A, Lisbon A. Anesthetic considerations in patients with mitochondrial dysfunction. Anesth Analg . 1993; 76 884-886
- 9 Schenkman K A, Yan S. Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectant spectroscopy. Crit Care Med . 2000; 28 172-177
- 10 Przyrembel H. Therapy of mitochondrial diseases. J Inherit Metab Dis . 1987 (suppl 1); 10 (129-146)
- 11 Taivassalo T, De Stefano N, Argov Z. Effects of aerobic training in patients with mitochondrial myopathies. Neurology . 1998; 50 1055-1060
- 12 Stacpoole P W, Henderson G N, Yan Z, Cornett R, James M O. Pharmacokinetics, metabolism, and toxicology of dichloroacetate. Drug Metab Rev . 1998; 30 499-539
- 13 Stacpoole P W, Barnes C L, Hurbanis M D, Cannon S L, Kerr D S. Treatment of congenital lactic acidosis with dichloroacetate. Arch Dis Child . 1997; 77 535-541
- 14 Stacpoole P W, Lorenz A C, Thomas R G, Harman E M. Dichloroacetate in the treatment of lactic acidosis. Ann Inter Med . 1988; 108 58-63
- 15 Stacpoole P W, Wright E C, Baumgartner T G. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. N Engl J Med . 1992; 327 1564-1569
- 16 Kuroda Y, Ito M, Naito E. Concomitant administration of sodium dichloroacetate and vitamin B1 for lactic acidemia in children with MELAS syndrome. J Pediatr . 1997; 131 450-452
- 17 Saijo T, Naito E, Ito M, Takeda E, Hashimoto T, Kuroda Y. Therapeutic effect of sodium dichloroacetate on visual and auditory hallucinations in a patient with MELAS. Neuropediatrics . 1991; 22 166-167
- 18 Kimura S, Osaka H, Saitou K, Ohtuki N, Kobayashi, N ezu. Improvement of lesions shown on MRI and CT scan by administration of dichloroacetate in patients with Leigh syndrome. J Neurol Sci . 1995; 134 103-107
- 19 Tulinius M H, Eriksson B O, Hjalmarson O, Holme E, Oldfors A. Mitochondrial myopathy and cardiomyopathy in siblings. Pediatr Neurol . 1989; 5 182-188
- 20 Takanashi J, Sugita K, Tanabe Y, Maemoto T, Niimi H. Dichloroacetate treatment in Leigh syndrome caused by mitochondrial DNA mutation. J Neurol Sci . 1997; 145 83-86
- 21 DeStefano N, Matthews P M, Ford B, Genge A, Karpati G, Arnold D L. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology . 1995; 45 1193-1198
- 22 Pavlakis S G, Kingsley P B, Kaplan G P, Stacpoole P W, O'Shea M, Lustbader D. Magnetic resonance spectroscopy: use in monitoring MELAS treatment. Arch Neurol . 1998; 55 849-852
- 23 Kimura S, Ohtuki N, Nezu A, Tanaka M, Takeshita S. Clinical and radiologic improvements in mitochondrial encephalomyopathy following sodium dichloroacetate therapy. Brain Dev . 1997; 19 535-540
- 24 Ogasahara S, Engel A, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A . 1989; 86 2379-2382
- 25 Goda S, Hamada T, Ishimoto S, Kobayashi T, Goto I, Kuroiwa Y. Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol . 1987; 234 62-63
- 26 Ogasahara S, Yorifuji S, Nishikawa Y. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. Neurology . 1985; 35 372-377
- 27 Bresolin N, Bet L, Binda A. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology . 1988; 38 892-899
- 28 Abe K, Fujimura H, Nishikawa Y. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol Scand . 1991; 83 356-359
- 29 Chen R S, Huang C C, Chu N S. Coenzyme Q10 treatment in mitochondrial encephalomyopathies: short-term double-blind, crossover study. Eur Neurol . 1997; 37 212-218
- 30 Chan A, Reichmann H, Koegel A, Beck A, Gold R. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol . 1998; 245 681-685
- 31 Bresolin N, Doriguzzi C, Ponzetto C. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci . 1990; 100 70-78
- 32 Zierz S, von Wersebe O, Bleistein J, Jerusalem F. Exogenous coenzyme Q (CoQ) fails to increase CoQ in skeletal muscle of two patients with mitochondrial myopathies. J Neurol Sci . 1990; 95 283-290
- 33 Matthews P M, Ford B, Dandurand R J. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology . 1993; 43 884-890
- 34 Eleff S M, Barker P B, Blackband S J. Phosphorous magnetic resonance spectroscopy of patients with mitochondrial cytopathies demonstrates decreased levels of brain phosphocreatine. Ann Neurol . 1990; 27 626-630
- 35 Argov Z, Bank W J. Phosphorous magnetic resonance spectroscopy (31P MRS) in neuromuscular disorders. Ann Neurol . 1991; 30 90-92
- 36 Gold R, Seibel P, Reinelt G. Phosphorous magnetic resonance spectroscopy in the evaluation of mitochondrial myopathies: results of a 6-month therapy study with coenzyme Q. Eur Neurol . 1996; 36 191-196
- 37 Barbiroli B, Iotti S, Lodi R. Improved brain and muscle mitochondrial respiration with CoQ: an in vivo study by 31P-MR spectroscopy in patients with mitochondrial cytopathies. BioFactors . 1999; 9 253-260
- 38 Bendahan D, Desnuelle C, Vanuxen D. 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. Neurology . 1992; 42 1203-1209
- 39 Cortelli P, Montagna P, Pierangeli G. Clinical and brain bioenergetics improvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and 31P-MRS study. J Neurol Sci . 1997; 148 25-31
- 40 Mashima Y, Hiida Y, Oguchi Y. Remission of Leber's hereditary optic neuropathy with idebenone. Lancet . 1992; 340 368-369
- 41 Ihara Y, Namba R, Kuroda S, Sato T, Shirabe T. Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. J Neurol Sci . 1989; 90 263-271
- 42 Schmidt-Sommerfield E, Werner D, Penn D. Carnitine plasma concentrations in 353 metabolically healthy children. Eur J Pediatr . 1988; 147 356-360
- 43 Angelini C, Vergani L, Martinuzzi A. Clinical and biochemical aspects of carnitine deficiency and insufficiency: transport defects and inborn errors of beta-oxidation. Crit Rev Clin Lab Sci . 1992; 29 217-242
- 44 Pons R, DeVivo D C. Primary and secondary carnitine deficiency syndromes. J Child Neurology . 1995 (suppl 2); 10 (9-24)
- 45 Carter A L, Abney T O, Lapp D F. Biosynthesis and metabolism of carnitine. J Child Neurol . 1995 (suppl 2); 10 (3-7)
- 46 Bellei M, Battelli D, Guarriero D M. Changes in mitochondrial activity caused by ammonium salts and the protective effect of carnitine. Biochem Biophys Res Commun . 1989; 158 181-188
- 47 Campos Y, Huertas R, Lorenzo G. Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve . 1993; 16 150-153
- 48 Harris R C, Soderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci . 1992; 83 367-374
- 49 Tarnopolsky M A, Roy B D, MacDonald J R. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve . 1997; 20 1502-1509
- 50 Tarnopolsky M A, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology . 1999; 52 854-857
- 51 Odland L M, MacDougall J D, Tarnopolsky M A, Elorriaga A, Borgmann A. The effect of oral Cr supplementation on muscle [PCr] and short-term maximal power output. Med Sci Sports Exerc . 1997; 29 216-219
- 52 Penn A MW, Lee J WK, Thuillier P. MELAS syndrome with mitochondrial tRNALeu(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology . 1992; 42 2147-2152
- 53 Griebel V, Kraegeloh-Mann I, Ruitenbeek W, Trijbels J MF, Paulus W. A mitochondrial myopathy in an infant with lactic acidosis. Dev Med Child Neurol . 1990; 32 528-531
- 54 Bernsen P J A L, Gabreels F JM, Ruitenbeek W, Hamburger H L. Treatment of complex I deficiency with riboflavin. J Neurol Sci . 1993; 118 181-187
- 55 Arts W FM, Scholte H R, Bogaard J M, Kerrebijn K F, Luyt-Houwen I EM. NADH-CoQ reductase deficient myopathy: successful treatment with riboflavin. Lancet . 1983; 2 581-582
- 56 Bernsen P J A L, Gabreels F JM, Ruitenbeek W, Sengers R CA, Stadhouders A M, Renier W O. Successful treatment of pure myopathy, associated with complex I deficiency, with riboflavin and carnitine. Arch Neurol . 1991; 48 334-338
- 57 Ogle R F, Christodoulou J, Fagan E. Mitochondrial myopathy with tRNALeu(URR) mutation and complex I deficiency responsive to riboflavin. J Pediatr . 1997; 130 138-145
- 58 Hoppel C L, Kerr D S, Dahms B, Roessmann U. Deficiency of the reduced nicotinamide adenine dinucleotide dehydrogenase component of complex I of mitochondrial electron transport. J Clin Invest . 1987; 80 71-77
- 59 Ichiki T, Tanaka M, Nishikimi M. Deficiency of subunits of complex I and mitochondrial encephalomyopathy. Ann Neurol . 1988; 23 287-294
- 60 Lou H C. Correction of increased plasma pyruvate and plasma lactate levels using large doses of thiamine in patients with Kearns-Sayre syndrome. Arch Neurol . 1981; 38 469
- 61 Mastaglia F L, Thompson P L, Papadimitriou J M. Mitochondrial myopathy with cardiomyopathy, lactic acidosis: response to prednisone and thiamine. Aust N Z J Med . 1980; 10 660-664
- 62 Cooper J M, Hayes D J, Challiss R AJ, Morgan-Hughes J A, Clark J B. Treatment of experimental NADH ubiquinone reductase deficiency with menadione. Brain . 1992; 115 991-1000
- 63 Eleff S, Kennaway N G, Buist N RM. 31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle. Proc Natl Acad Sci U S A . 1984; 81 3529-3533
- 64 Argov Z, Bank W J, Maris J. Treatment of mitochondrial myopathy due to complex III deficiency with vitamins K3 and C: a 31P-NMR follow-up study. Ann Neurol . 1986; 19 598-602
- 65 Toscano A, Fazio M C, Vita G. Early-onset cerebellar ataxia, myoclonus and hypogonadism in a case of mitochondrial complex III deficiency treated with vitamins K3 and C. J Neurol . 1995; 242 203-209
- 66 Allen R J, DiMauro S, Coulter D C, Papadimitriou A, Rothenberg S P. Kearns-Sayre syndrome with reduced plasma and cerebrospinal fluid folate. Ann Neurol . 1983; 13 679-682
- 67 Peterson P L. The treatment of mitochondrial myopathies and encephalomyopathies. Biochimica Biophysica Acta . 1995; 1271 275-280
- 68 Artuch R, Vilaseca M A, Pineda M. Biochemical monitoring of the treatment in paediatric patients with mitochondrial disease. J Inherit Metab Dis . 1998; 21 837-845
- 69 Barbiroli B, Medori R, Tritschler H J. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy. J Neurol . 1995; 242 472-477